Allogeneic Stem Cells
Allogeneic Stem Cells - Related Videos
08:52
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
0 Views •
Cited by 49 •
2011
A rapid, simple and cost-effective protocol for the generation of donor-derived multivirus-specific CTLs (rCTL) for infusion to allogeneic hematopoietic stem cell transplant (HSCT) recipients at risk of developing CMV, Adv or EBV infections. This manufacturing process is GMP-compliant and should ensure the broader implementation of T-cell immunotherapy beyond specialized centers.
11:22
Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots
0 Views •
Cited by 32 •
2013
An experimental technique for the treatment of osteochondral defects in the rabbit's knee joint is described. The implantation of allogeneic mesenchymal stem cells into osteochondral defects provides a promising development in the field of tissue engineering. The preparation of fibrin-cell-clots in vitro offers a standardized method for implantation.
06:48
Transplantation of Tail Skin to Study Allogeneic CD4 T Cell Responses in Mice
0 Views •
Cited by 10 •
2014
Tail-skin transplantation is a powerful model for studying T cell-dependent rejection and tolerance induction during allogeneic immune responses in mice. The advantages of this protocol are minor invasive surgery, and ease of monitoring with no need to sacrifice the recipient mouse.
22:06
Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
0 Views •
Cited by 7 •
2007
This protocol details the derivation of transplantable hematopoietic stem cells from mouse embryonic stem cells (ESC) and their subsequent injection into lethally irradiated recipient mice. Briefly, ESC are differentiated as embryoid bodies, which are then infected with retroviral HoxB4 and co-cultured with OP9 stromal cells and hematopoietic cytokines.
05:54
Induction of Graft Versus Host Disease in Mouse Models via Allogeneic Bone Marrow and Splenic Cell Transplantation
0 Views •
2025
This video demonstrates the induction of intestinal graft-versus-host disease, GvHD, in a lethally-irradiated recipient mouse using allogeneic hematopoietic stem cells and GvHD-inducing splenic alloreactive T lymphocytes. This protocol helps establish a severe acute intestinal GvHD model to understand the mechanism of the disease and develop innovative therapeutic options.
FAQs
Compatibility between donor and recipient human leukocyte antigens, or HLA, helps donor cells function in the recipient while reducing immune complications. Better matching can limit rejection of the graft and decrease graft-versus-host disease, in which donor immune cells react against recipient tissues. HLA relationships therefore affect both transplant success and immune outcomes.
After transfer, hematopoietic donor cells home to the recipient’s bone marrow and engraft, meaning they establish themselves there and begin producing new blood-forming and immune cells. This process can reconstitute immune function as well as blood-cell production. Its success is central to restoring systems damaged by marrow failure, malignancy, or immune deficiency.
Donor immune cells may recognize and eliminate residual cancer cells, creating a graft-versus-leukemia effect that contributes to treatment. However, immune differences between donor and recipient can also promote graft-versus-host disease. These opposing outcomes show why donor immune activity is clinically important: it may strengthen cancer control while also creating a major transplant complication.
The essential sequence is donor-cell transfer, homing to the recipient’s bone marrow, engraftment, and generation of new blood-forming and immune cells. Donor-recipient HLA compatibility is considered because it helps limit rejection and graft-versus-host disease. Together, these steps determine whether the transplant can rebuild the recipient’s hematopoietic and immune systems.
Allogeneic stem-cell transplantation is used for leukemia, lymphoma, marrow failure, and certain immune deficiencies. The rationale differs by condition but centers on replacing or rebuilding damaged blood-forming and immune systems. In leukemia, donor immune activity can also help remove residual malignant cells through a graft-versus-leukemia effect, adding an immune-mediated treatment benefit.
These transplants provide a model for examining immune reconstitution after donor cells establish themselves in the recipient. Researchers can investigate how newly formed immune cells, immunosuppression, and donor-recipient interactions influence susceptibility to pathogens and transplant outcomes. This makes the approach relevant not only to transplantation, but also to understanding infection risk during altered immune states.